UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.
Search Articles
Journal of controlled release, ISSN 0168-3659, 06/2015, Volume 207, pp. 18 - 30
Oxidative stress | Neuroinflammation | Parkinson's disease | Catalase | Exosomes | Blood–brain barrier | Blood-brain barrier | Pharmacology & Pharmacy | Physical Sciences | Chemistry | Life Sciences & Biomedicine | Chemistry, Multidisciplinary | Science & Technology | Antioxidants - chemistry | Antioxidants - metabolism | Oxidopamine | Anti-Inflammatory Agents - metabolism | PC12 Cells | Neuroprotective Agents - metabolism | Drug Carriers | Brain - metabolism | Nanoparticles | Parkinsonian Disorders - metabolism | Parkinsonian Disorders - drug therapy | Antiparkinson Agents - chemistry | Anti-Inflammatory Agents - administration & dosage | Female | Neurons - metabolism | Neuroprotective Agents - administration & dosage | Nanomedicine | Disease Models, Animal | Neuroprotective Agents - chemistry | Mice, Inbred C57BL | Solubility | Rats | Technology, Pharmaceutical - methods | Parkinsonian Disorders - chemically induced | Administration, Intranasal | Chemistry, Pharmaceutical | Brain - drug effects | Catalase - metabolism | Catalase - administration & dosage | Animals | Anti-Inflammatory Agents - chemistry | Antioxidants - administration & dosage | RAW 264.7 Cells | Antiparkinson Agents - administration & dosage | Mice | Kinetics | Oxidative Stress - drug effects | Antiparkinson Agents - metabolism | Catalase - chemistry | Drugs | Drug delivery systems | Proteases | Analysis | Antiparkinsonian agents | Vehicles | Index Medicus | blood-brain barrier | neuroinflammation | exosomes | catalase | oxidative stress | Parkinson’s disease
Journal Article
Current medicinal chemistry, ISSN 0929-8673, 04/2011, Volume 18, Issue 10, pp. 1464 - 1475
Antioxidants | Antitumor agents | Parkinson's disease | Natural products | Alzheimer's disease | Neurodegenerative disorders | Cancer | Hybrid molecules | Pharmacology & Pharmacy | Biochemistry & Molecular Biology | Life Sciences & Biomedicine | Chemistry, Medicinal | Science & Technology | Antioxidants - chemistry | Antineoplastic Agents - chemical synthesis | Humans | Alzheimer Disease - drug therapy | Antimalarials - therapeutic use | Antineoplastic Agents - therapeutic use | Structure-Activity Relationship | Antioxidants - chemical synthesis | Antineoplastic Agents - chemistry | Neurodegenerative Diseases - drug therapy | Neoplasms - drug therapy | Antioxidants - therapeutic use | Biological Products - chemistry | Animals | Antimalarials - chemistry | Drug Design | Pharmaceutical Preparations - chemistry | Biological Products - administration & dosage | Pharmaceutical Preparations - administration & dosage | Antimalarials - chemical synthesis
Journal Article
Journal of cellular physiology, ISSN 0021-9541, 06/2019, Volume 234, Issue 6, pp. 8496 - 8508
Hypericum perforatum | anxiety | neurodegenerative diseases | depression | psychiatric disorders | Physiology | Life Sciences & Biomedicine | Science & Technology | Cell Biology | Antiparkinson Agents - isolation & purification | Hypericum - adverse effects | Humans | Nootropic Agents - isolation & purification | Nootropic Agents - therapeutic use | Plant Extracts - isolation & purification | Anti-Anxiety Agents - isolation & purification | Nootropic Agents - adverse effects | Antiparkinson Agents - adverse effects | Antidepressive Agents - isolation & purification | Antidepressive Agents - therapeutic use | Antiparkinson Agents - therapeutic use | Animals | Anti-Anxiety Agents - adverse effects | Anti-Anxiety Agents - therapeutic use | Antidepressive Agents - adverse effects | Plant Extracts - therapeutic use | Hypericum - chemistry | Plant Extracts - adverse effects | Nervous system | Care and treatment | Degeneration | Health aspects | Depression, Mental | Antidepressants, Tricyclic | Medical research | Effectiveness | Mental disorders | Neurodegenerative diseases | Serotonin | Mental health | Disorders | Clinical trials | Serotonin uptake inhibitors | Mental depression | Quality of life | Herbal medicine | Side effects | Properties (attributes) | Hypericin | Antidepressants | Tricyclic antidepressants | In vivo methods and tests | Anxiety | Index Medicus
Journal Article
Epilepsy research, ISSN 0920-1211, 2011, Volume 98, Issue 2, pp. 194 - 198
Neurology | Antiepileptic drug | Polytherapy | Seizure | Epilepsy | Combination | Clinical Neurology | Neurosciences & Neurology | Life Sciences & Biomedicine | Science & Technology | Pharmacology. Drug treatments | Headache. Facial pains. Syncopes. Epilepsia. Intracranial hypertension. Brain oedema. Cerebral palsy | Biological and medical sciences | Anticonvulsants. Antiepileptics. Antiparkinson agents | Medical sciences | Neuropharmacology | Nervous system (semeiology, syndromes) | Humans | Middle Aged | Anticonvulsants - therapeutic use | Male | Treatment Outcome | Young Adult | Drug Therapy, Combination - methods | Drug Interactions | Adolescent | Aged, 80 and over | Adult | Drug Therapy, Combination - statistics & numerical data | Epilepsy - drug therapy | Female | Aged | Retrospective Studies | Drug Combinations | Anticonvulsants | Index Medicus
Journal Article
European journal of medicinal chemistry, ISSN 0223-5234, 2010, Volume 45, Issue 12, pp. 5541 - 5560
2-Azetidinone | β-Lactam | Biological activity | Four membered heterocyclic ring | Pharmacology & Pharmacy | Life Sciences & Biomedicine | Chemistry, Medicinal | Science & Technology | Biological and medical sciences | Miscellaneous | Medical sciences | Pharmacology. Drug treatments | Antifungal Agents - pharmacology | Animals | Antiparkinson Agents - pharmacology | Anti-Infective Agents - chemistry | Anti-Infective Agents - pharmacology | Humans | Antiparkinson Agents - chemistry | Antifungal Agents - chemistry | Hypoglycemic Agents - chemistry | Azetidines - pharmacology | Azetidines - chemistry | Hypoglycemic Agents - pharmacology | Index Medicus
Journal Article
Bioorganic & medicinal chemistry letters, ISSN 0960-894X, 12/2012, Volume 22, Issue 23, pp. 7029 - 7035
Petra/Osiris/Molinspiration/ALOGPS 2.1 program | Anti-HIV | Antifungal | Tautomerism | Anticonvulsant | Antibacterial | Pyrazolines | Antiviral agents | Pharmacology. Drug treatments | Antifungal agents | Biological and medical sciences | Anticonvulsants. Antiepileptics. Antiparkinson agents | Medical sciences | Neuropharmacology | Antibacterial agents | Antibiotics. Antiinfectious agents. Antiparasitic agents | Anti-HIV Agents - pharmacology | Anti-HIV Agents - toxicity | Amides - chemical synthesis | Escherichia coli - drug effects | Humans | Motor Activity - drug effects | Antifungal Agents - chemical synthesis | Antifungal Agents - chemistry | Anticonvulsants - pharmacology | Microbial Sensitivity Tests | Pyrazoles - chemistry | Candida albicans - drug effects | Anti-Bacterial Agents - chemistry | Antifungal Agents - pharmacology | Cell Line | Cell Survival - drug effects | Thioamides - chemistry | Anticonvulsants - chemical synthesis | HIV-1 - drug effects | Computational Biology | Pseudomonas aeruginosa - drug effects | Anti-Bacterial Agents - chemical synthesis | HIV-2 - drug effects | Anti-HIV Agents - chemistry | Animals | Anticonvulsants - chemistry | Amides - chemistry | Thioamides - chemical synthesis | Anti-Bacterial Agents - pharmacology | Aspergillus niger - drug effects | Mice | Staphylococcus aureus - drug effects | Bacillus subtilis - drug effects | Research institutes | Heterocyclic compounds | Index Medicus
Journal Article
Dementia and geriatric cognitive disorders, ISSN 1420-8008, 02/2013, Volume 35, Issue 1-2, pp. 1 - 22
Paper | Tauopathies | Pharmacology, clinical | Drug effects | Therapeutics | Amyloid β-peptides | Clinical trials | Amyloid | Drug therapy | Tau proteins | Dementia | Clinical Neurology | Neurosciences & Neurology | Life Sciences & Biomedicine | Psychiatry | Geriatrics & Gerontology | Science & Technology | Neurology | Biological and medical sciences | Vascular diseases and vascular malformations of the nervous system | Medical sciences | Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases | Hypoglycemic Agents - therapeutic use | Nicotine - therapeutic use | Anti-Asthmatic Agents - therapeutic use | Humans | Alzheimer Disease - drug therapy | Anticonvulsants - therapeutic use | Antineoplastic Agents - therapeutic use | Antihypertensive Agents - therapeutic use | Nicotinic Agonists - therapeutic use | Drug Discovery | Antidepressive Agents - therapeutic use | Antiparkinson Agents - therapeutic use | Anti-Bacterial Agents - therapeutic use | Anti-Inflammatory Agents, Non-Steroidal - therapeutic use | Antipsychotic Agents - therapeutic use | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Methylene Blue - therapeutic use | Aged | Index Medicus
Journal Article
International journal of biological macromolecules, ISSN 0141-8130, 06/2013, Volume 57, pp. 165 - 173
Heterocyclic candidates | Hypoglycemic and anti-microbial activities | Poly ring systems | Anti-parkinsonism | Biochemistry & Molecular Biology | Physical Sciences | Chemistry | Life Sciences & Biomedicine | Chemistry, Applied | Polymer Science | Science & Technology | Antiparkinson Agents - pharmacology | Anti-Infective Agents - pharmacology | Heterocyclic Compounds, 2-Ring - chemistry | Antiparkinson Agents - chemical synthesis | Hypoglycemic Agents - chemistry | Candida albicans - growth & development | Anti-Infective Agents - chemical synthesis | Heterocyclic Compounds, 2-Ring - pharmacology | Hypoglycemic Agents - pharmacology | Bacteria - growth & development | Animals | Anti-Infective Agents - chemistry | Hypoglycemic Agents - chemical synthesis | Parkinson Disease, Secondary - drug therapy | Antiparkinson Agents - chemistry | Aspergillus fumigatus - growth & development | Mice | Parkinson Disease, Secondary - chemically induced | Heterocyclic Compounds, 2-Ring - chemical synthesis | Drugstores | Parkinson's disease | Pyridine | Antiparkinsonian agents | Index Medicus
Journal Article